Vir Biotechnology (NASDAQ:VIR) CAO Brent Sabatini Sells 1,530 Shares

Vir Biotechnology, Inc. (NASDAQ:VIR) CAO Brent Sabatini sold 1,530 shares of Vir Biotechnology stock in a transaction dated Friday, February 13th. The shares were sold at an average price of $7.79, for a total value of $11,918.70. Following the completion of the transaction, the chief accounting officer owned 47,872 shares of the company’s stock, valued at $372,922.88. The trade was a 3.10% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this link.

Vir Biotechnology Stock Performance

NASDAQ VIR traded up $0.32 during trading hours on Wednesday, hitting $7.82. The company had a trading volume of 1,308,854 shares, compared to its average volume of 1,784,829. The business has a 50 day moving average of $6.66 and a 200-day moving average of $5.87. The company has a market cap of $1.09 billion, a PE ratio of -2.16 and a beta of 1.69. Vir Biotechnology, Inc. has a 1-year low of $4.16 and a 1-year high of $9.97.

Wall Street Analyst Weigh In

Several equities analysts recently commented on the company. Needham & Company LLC reiterated a “buy” rating and issued a $14.00 target price on shares of Vir Biotechnology in a research note on Monday, February 9th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Vir Biotechnology in a research note on Monday, December 22nd. Barclays set a $26.00 price target on Vir Biotechnology in a research note on Tuesday. Finally, HC Wainwright reissued a “buy” rating and issued a $15.00 target price on shares of Vir Biotechnology in a report on Tuesday, December 30th. Seven research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of $16.29.

Hedge Funds Weigh In On Vir Biotechnology

A number of hedge funds have recently made changes to their positions in VIR. ARCH Venture Management LLC acquired a new stake in Vir Biotechnology in the second quarter valued at approximately $65,100,000. VIRGINIA RETIREMENT SYSTEMS ET Al purchased a new stake in Vir Biotechnology during the second quarter worth about $289,000. Allianz Asset Management GmbH grew its holdings in Vir Biotechnology by 6.2% during the second quarter. Allianz Asset Management GmbH now owns 327,700 shares of the company’s stock valued at $1,652,000 after purchasing an additional 19,000 shares during the period. Ensign Peak Advisors Inc boosted its position in Vir Biotechnology by 812.7% during the second quarter. Ensign Peak Advisors Inc now owns 582,981 shares of the company’s stock worth $2,938,000 after purchasing an additional 519,107 shares during the period. Finally, Corton Capital Inc. bought a new stake in Vir Biotechnology during the 2nd quarter valued at $114,000. 65.32% of the stock is currently owned by institutional investors.

About Vir Biotechnology

Vir Biotechnology, Inc is a clinical‐stage immunology company dedicated to developing therapies that prevent and treat serious infectious diseases. The company leverages a suite of proprietary technology platforms—ranging from antibody isolation and screening tools to cell‐based assays and bioinformatics—to identify and advance antiviral and antibacterial candidates. Its scientific approach centers on harnessing the human immune system through monoclonal antibodies and immunomodulatory agents.

The company’s pipeline includes product candidates targeting influenza A, COVID‐19, HIV, hepatitis B, and tuberculosis.